Latest News and Press Releases

MALVERN, Pa., Dec. 4, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the...

MALVERN, Pa., Dec. 2, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that company management will participate in the following conferences in New York...

MALVERN, Pa., Nov. 10, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the...

MALVERN, Pa., Nov. 7, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as Class I...

MALVERN, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...

MALVERN, Pa., Nov. 3, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the company will host a live audio webcast in conjunction with its Investor...

MALVERN, Pa., Aug. 27, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the preclinical studies that provide the rationale for SMAC-mimetics...

MALVERN, Pa., June 24, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company" ) announced the closing of its previously-announced offering of $47 million...

MALVERN, Pa., June 17, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company") announced the pricing of its offering of $47 million in aggregate principal amount...

MALVERN, Pa., June 13, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) ("Company") today announced that it will host a conference call and live audio webcast on Monday,...